BioSpace News Archive

Adamis Pharmaceuticals Corporation announced financial results for the full year ended December 31, 2022, and provided an update on recent corporate developments.

Lifecore Biomedical, Inc. announced that it has entered into a term sheet to seek to expand its existing CDMO relationship with one of its long-term commercial Hyaluronic Acid and CDMO customers, including obtaining certain up-front cash payments and capital reimbursement obligations from the customer and entering into a non-binding agreement to amend the current contract manufacturing agreement with the customer to extend and expand the existing relationship.

Predictive Oncology Inc. today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on March 27, 2023.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) will present an ePoster with an oral presentation at the American Academy of Dermatology (AAD) Annual Meeting, highlighting clinical data from RUBY-1, a phase 1 healthy volunteer (HV) study of povetacicept, a dual B cell cytokine antagonist being developed for multiple B cell and/or autoantibody-related diseases.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 490,630 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it plans to implement a ratio change of the Company’s American Depositary Shares to its non-traded ordinary shares from the current ratio of one ADS representing ten ordinary shares to a new ratio of one ADS representing four hundred ordinary shares.

Vaccine development company Matrivax announces the start of its Phase 1 clinical study to assess the safety, tolerability, and immunogenicity of its lead pneumococcal disease vaccine candidate, MVX01.

Curia today announced that Philip Macnabb has been appointed as chief executive officer, succeeding John Ratliff.

Novartis announced the U.S. Food and Drug Administration granted approval for Tafinlar® + Mekinist® for the treatment of pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.

CANbridge Pharmaceuticals, Inc. announced that long-term follow up data from the Phase 1/2 study of CAN008 plus temozolomide/radiotherapy in newly diagnosed glioblastoma multiforme showed a long-term survival rate of 67% at five years, three years after the trial ended.